Floatz logo

a2b543

Mesothelioma

A2 Biotherapeutics Inc.Cell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Mesothelioma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Fludarabine
National Cancer Institute (NCI)
Phase 2B
Nivolumab
Orion Corporation, Orion Pharma
Phase 2B
Pembrolizumab
Genmab
Phase 2B
FLUDEOXYGLUCOSE
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

a2b543 is also rated in:

non-small cell squamous lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
malignant mesotheliomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →